Department of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA.
Department of Chemistry and Stanford ChEM-H, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford, CA 94305, USA.
Cell Chem Biol. 2021 Jul 15;28(7):1072-1080. doi: 10.1016/j.chembiol.2021.02.024. Epub 2021 Mar 25.
Targeted protein degradation (TPD) is a promising strategy to remove deleterious proteins for therapeutic benefit and to probe biological pathways. The past two decades have witnessed a surge in the development of technologies that rely on intracellular machinery to degrade challenging cytosolic targets. However, these TPD platforms leave the majority of extracellular and membrane proteins untouched. To enable degradation of these classes of proteins, internalizing receptors can be co-opted to traffic extracellular proteins to the lysosome. Sweeping antibodies and Seldegs use Fc receptors in conjunction with engineered antibodies to degrade soluble proteins. Recently, lysosome-targeting chimeras (LYTACs) have emerged as a strategy to degrade both secreted and membrane-anchored targets. Together with other newcomer technologies, including antibody-based proteolysis-targeting chimeras, modalities that degrade extracellular proteins have promising translational potential. This perspective will give an overview of TPD platforms that degrade proteins via outside-in approaches and focus on the recent development of LYTACs.
靶向蛋白降解(TPD)是一种很有前途的策略,可以去除有害蛋白以达到治疗效果,并探测生物途径。在过去的二十年中,依赖于细胞内机制来降解具有挑战性的细胞质靶标的技术得到了迅猛发展。然而,这些 TPD 平台对大多数细胞外和膜蛋白都无动于衷。为了能够降解这些类别的蛋白,可以利用内化受体将细胞外蛋白运送到溶酶体。Sweeping 抗体和 Seldegs 利用 Fc 受体与工程抗体结合来降解可溶性蛋白。最近,溶酶体靶向嵌合体(LYTAC)作为一种降解分泌蛋白和膜锚定靶标的策略出现了。与其他新技术一起,包括基于抗体的蛋白水解靶向嵌合体,降解细胞外蛋白的方法具有很有前景的转化潜力。本文将概述通过外向途径降解蛋白的 TPD 平台,并重点介绍 LYTAC 的最新发展。